<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen J Tietze, PharmD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barry Fuchs, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Polly E Parsons, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael F O'Connor, MD, FCCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Distress due to pain, fear, anxiety, dyspnea, or delirium is common among critically ill patients, especially those who are intubated or are having difficulty communicating with their caregivers. Distress may manifest clinically as agitation that is often associated with ventilator asynchrony and increased sympathetic tone, which may have untoward clinical effects.</p><p>The mechanism of action, efficacy, properties, dosing, and adverse effects of common sedative-analgesic medications used to treat distress in critically ill adults are reviewed in this topic. Selecting the optimal sedative-analgesic strategy and management of pain and neuromuscular blockade in critically ill patients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a> and  <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient"</a> and  <a class="medical medical_review" href="/z/d/html/1590.html" rel="external">"Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects"</a>.)</p><p class="headingAnchor" id="H208693587"><span class="h1">CHOOSING AGENT</span><span class="headingEndMark"> — </span>No sedative-analgesic agent is sufficiently superior to warrant its use in all clinical situations. As a result, selection of an agent must be individualized according to pharmacokinetic variables (eg, potential interactions with other drugs) and nonpharmacokinetic variables (eg, renal and liver failure, presence of bradycardia or hypotension), the etiology of the distress, and the desired depth of sedation. The selection of sedative agents in the critically ill patient is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Selection of agent(s)'</a>.)</p><p class="headingAnchor" id="H970065"><span class="h1">ANALGESICS</span><span class="headingEndMark"> — </span>Pain is a common reason for agitation in critically ill patients. Pain is managed with opioid and nonopioid analgesic agents.</p><p class="headingAnchor" id="H971743"><span class="h2">Opioid analgesics</span><span class="headingEndMark"> — </span>The most common opioids used to manage distress due to pain in critically ill patients are <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, and <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> sulphate. They can be administered as intermittent dosing or continuous infusions. Oral opioids such as <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, and morphine are also given to patients when oral or enteral administration is preferred. <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">Remifentanil</a> is also an option. Choice of opioid analgesic and their individual properties are discussed in detail separately  (<a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient", section on 'Opioid analgesics'</a>.)</p><p class="headingAnchor" id="H971750"><span class="h2">Nonopioid analgesics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a> (enteral or intravenous [IV]), nonsteroidal anti-inflammatory agents, IV <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, and IV <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> can be used as alternatives or additives to opioids for the management of nonneuropathic pain in the intensive care unit (ICU)  (<a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">table 1</a>). Additionally, they can be used as opioid-sparing agents to reduce or eliminate the need for opioids in critically ill adult patients [<a href="#rid1">1</a>]. Enteral <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, and/or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, in addition to IV opioids, can be used to treat neuropathic pain in adult ICU patients. Use of nonopioid analgesics is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient", section on 'Nonopioid analgesics'</a>.)</p><p class="headingAnchor" id="H970645"><span class="h1">PROPOFOL</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a> is an intravenous (IV) anesthetic that is commonly used for sedation of the agitated adult intensive care unit (ICU) patient.</p><p class="headingAnchor" id="H970847"><span class="h2">Mechanism</span><span class="headingEndMark"> — </span>Activation of the central gamma-aminobutyric acid (GABA) type A receptors with modulation of hypothalamic sleep pathways appears to be the mechanism by which <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> exerts its effect [<a href="#rid2">2-5</a>]. Propofol has amnesic, anxiolytic, anticonvulsant, and muscle relaxant (including bronchodilation) effects. It has no direct analgesic effects.</p><p class="headingAnchor" id="H970854"><span class="h2">Properties</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a> is a highly lipophilic phenol derivative that is insoluble in water. Therefore, it is formulated as an emulsion of soybean oil, egg lecithin, and glycerol for IV administration. Although hypersensitivity reactions are rare, labeled contraindications include hypersensitivity to eggs, egg products, soy, or soy products [<a href="#rid6">6,7</a>].</p><p>The elimination of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> is not impaired by hepatic or renal dysfunction. Propofol has a large volume of distribution and is highly protein bound. Its rapid onset and short duration make it a useful agent in the ICU.</p><p class="bulletIndent1"><span class="glyph">●</span>Onset of action – <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a> has an onset of action of less than one minute because its high lipophilicity facilitates passage through the blood-brain barrier.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration of effect – <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a>'s duration of effect is 3 to 10 minutes during short-term use (&lt;48 hours). The short duration reflects the rapid metabolism of propofol by the liver and elsewhere to minimally active metabolites, which are renally excreted.</p><p></p><p class="bulletIndent1">Less is known about <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>'s duration of effect following long-term administration (eg, a few days). One study reported an elimination half-life of 31 hours after prolonged administration, suggesting that propofol's high lipophilicity leads to its accumulation in fatty tissues and prolonged sedation [<a href="#rid8">8</a>]. Another study reported a longer time to extubation in patients who received propofol for extended periods compared with patients receiving short-term sedation with propofol (&lt;24 hours); extubation was delayed by 10 minutes in patients on propofol for one to seven days and by 30 minutes for patients on propofol for greater than seven days [<a href="#rid9">9,10</a>].</p><p></p><p class="headingAnchor" id="H970868"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span>A typical dose regimen for <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> is listed in the table  (<a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. A loading dose is not typically administered when a propofol infusion is started in the ICU for sedation unless a bolus dose is required for emergency care (eg, intubation, transport, procedures).</p><p><a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a> is administered by continuous infusion in the ICU and not by intermittent bolus because it is associated with dose- and rate-dependent hypotension.</p><p>The manufacturer recommends that the bottles and tubing be discarded every 12 hours and that line integrity be maintained to minimize the risk of bacterial contamination.</p><p>When administered peripherally, <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> is generally given through a large-bore IV catheter (often in the antecubital fossa) to reduce burning, stinging, and pain that can occur with peripheral administration.</p><p>During administration, we perform routine biochemical monitoring with a daily basic metabolic panel, triglycerides (eg, once daily for the first three days); if propofol-related infusion syndrome (PRIS) is suspected, we also measure serum lactate, creatinine kinase, and myoglobin. [<a href="#rid11">11</a>]. This approach may allow for the early identification of worrisome side effects (See <a class="local">'Adverse effects'</a> below.)</p><p><a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a> should be discontinued as soon as any significant abnormality is identified (eg, clinical suspicion for PRIS, high serum triglyceride concentration &gt;300 mg/dL). The upper limit of tolerance for hypertriglyceridemia is unknown. Data suggest that levels up to 300 mg/dL, sometimes 400 mg/dL is reasonable [<a href="#rid12">12-14</a>]. (See <a class="local">'Propofol-related infusion syndrome'</a> below.)</p><p class="headingAnchor" id="H970875"><span class="h2">Adverse effects</span></p><p class="headingAnchor" id="H3158328343"><span class="h3">General</span><span class="headingEndMark"> — </span>Hypotension is a common consequence of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> infusion, estimated to occur in approximately 25 percent of ICU patients who receive propofol for sedation [<a href="#rid15">15</a>]. Hypotension is frequent following bolus administration but can even occur with low-dose infusions. In an observational study of almost 26,000 patients receiving propofol anesthesia, 16 percent developed hypotension and over three-quarters of the hypotensive episodes occurred within 10 minutes of induction via a bolus infusion [<a href="#rid16">16</a>].</p><p>Other potential adverse effects of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> that are uncommon include bradycardia, arrhythmias, neuroexcitatory effects (seizure-like activity, myoclonus, choreoathetoid movements, meningismus), infections from contaminated vials or tubing, respiratory depression, pancreatitis, hypertriglyceridemia, anaphylaxis, and green or white discoloration of urine [<a href="#rid8">8,17-20</a>].</p><p>Unusual and potentially serious complications are associated with continuous infusion of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> for longer than 24 to 48 hours. These include progressive hypertriglyceridemia, pancreatitis, increased carbon dioxide production, and an excessive caloric load (the emulsion contains approximately 1.1 kcal/mL, most of which is derived from lipids). Despite these complications, a meta-analysis of 14 randomized trials reported that in critically ill patients, prolonged propofol infusions (&gt;24 hours) do not increase overall mortality compared with other sedatives (eg, benzodiazepines) [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H970882"><span class="h3">Propofol-related infusion syndrome</span><span class="headingEndMark"> — </span>PRIS is a rare complication of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> infusion (&lt;1 percent) with an unclear pathogenesis [<a href="#rid22">22,23</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – PRIS is characterized by one or more of the following that is otherwise unexplained [<a href="#rid22">22,24,25</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute refractory bradycardia, less commonly ventricular tachycardia or fibrillation, asystole, widened QRS complex</p><p class="bulletIndent2"><span class="glyph">•</span>Severe metabolic acidosis</p><p class="bulletIndent2"><span class="glyph">•</span>Cardiovascular collapse</p><p class="bulletIndent2"><span class="glyph">•</span>Rhabdomyolysis</p><p class="bulletIndent2"><span class="glyph">•</span>Hyperlipidemia</p><p class="bulletIndent2"><span class="glyph">•</span>Hyperkalemia</p><p class="bulletIndent2"><span class="glyph">•</span>Acute kidney injury</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatomegaly</p><p class="bulletIndent2"><span class="glyph">•</span>Transaminitis</p><p class="bulletIndent2"><span class="glyph">•</span>Fever</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for PRIS include high doses (&gt;4 mg/kg/hour or &gt;67 mcg/kg/min) and prolonged use (&gt;48 hours) [<a href="#rid22">22,24,26,27</a>], although it has also been reported with high-dose short-term infusions [<a href="#rid28">28,29</a>]. Additional proposed risk factors include young age, critical illness, high fat and low carbohydrate intake, inborn errors of mitochondrial fatty acid oxidation, and concomitant catecholamine infusion or glucocorticoid therapy [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – PRIS is a diagnosis of exclusion. Once PRIS is suspected, <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> should be stopped while investigations are ongoing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment involves immediate discontinuation of the <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> infusion and supportive care [<a href="#rid29">29</a>]. Successful use of extracorporeal membrane oxygenation has been described [<a href="#rid30">30,31</a>] as has hemofiltration to remove propofol rapidly from the body [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Mortality is variable but high (33 to 66 percent) [<a href="#rid22">22,24,33,34</a>]. Predictors of death vary among studies and are unclear [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Prevention involves monitoring during administration (eg, clinically and daily basic metabolic panel) (see <a class="local">'Dosing and administration'</a> above) and avoidance of high doses for prolonged periods [<a href="#rid11">11</a>]. We do not actively avoid concomitant glucocorticoid or vasopressor administration, but in patients with known or suspected mitochondrial dysfunction, we may consider using an alternate sedative since mitochondrial uncoupling has been implicated as a possible mechanism underlying PRIS [<a href="#rid35">35,36</a>].</p><p></p><p class="bulletIndent1">It is not known if a history of PRIS places patients at greater risk of PRIS upon re-exposure to the drug, but it is reasonable to avoid its use in such cases.</p><p></p><p class="headingAnchor" id="H970925"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>Central nervous system (CNS) and respiratory depressants (eg, opioid narcotics, benzodiazepines) enhance the CNS and respiratory depressant effect of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>. Propofol undergoes hepatic conjugation to inactive metabolites; thus, metabolically related drug interactions of major clinical importance have not been identified.</p><p class="headingAnchor" id="H970932"><span class="h1">DEXMEDETOMIDINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> is commonly used for sedation of mechanically ventilated patients.</p><p class="headingAnchor" id="H4196940067"><span class="h2">Mechanism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> is a highly selective, centrally acting alpha-2-agonist with anxiolytic, sedative, and some analgesic effects. While dexmedetomidine is a weak analgesic by itself, it potentiates the analgesic effects of opiates and endogenous enkephalins [<a href="#rid37">37,38</a>].</p><p class="headingAnchor" id="H4183599538"><span class="h2">Properties</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> is the dextro-enantiomer of medetomidine, a racemic mixture of the stereoisomers levomedetomidine and dexmedetomidine; dexmedetomidine is the main active isomer. Intravenous (IV) dexmedetomidine is available as a water soluble hydrochloride salt.</p><p><a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> undergoes extensive first pass metabolism resulting in low oral bioavailability. Absorbed across buccal and intranasal mucosae, intranasal dexmedetomidine is used off-label for pediatric procedural distress [<a href="#rid39">39</a>]. Dexmedetomidine is highly protein-bound to albumin and alpha1-glycoprotein, has a distribution half-life of approximately six minutes, and a variable volume of distribution of approximately 109 to 223 L in critically ill patients receiving long-term infusion [<a href="#rid40">40</a>].</p><p><a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> undergoes extensive hepatic biotransformation by multiple cytochrome P450 (CYP) enzymes with &lt;1 percent excreted unchanged. With a high hepatic extraction ratio of 0.7, dexmedetomidine clearance may be decreased in patients with significantly reduced cardiac output [<a href="#rid41">41</a>]. Other patient-specific factors such as hypoalbuminemia, end-organ damage, and hemodynamic variability contribute to the high interindividual variability in dexmedetomidine distribution volumes and clearance [<a href="#rid40">40</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Onset of action – <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> has an onset of action of approximately 15 to 20 minutes with continuous IV infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration of effect – <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> has an elimination half-life of 2.1 to 3 hours in normal volunteers and 2.2 to 3.7 hours in critically ill patients [<a href="#rid40">40</a>]. In intensive care unit patients receiving prolonged infusions (&gt;24 hours) the elimination half-life is even longer and more variable (mean 3.7 hours, range 2.4 to 6.9 hours) [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H1017352740"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> is administered as an infusion as outlined in the table  (<a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">table 1</a>).</p><p>An initial loading dose is typically not performed but can be administered, if necessary [<a href="#rid43">43</a>]. The initial loading dose may cause transient hypotension or hypertension, depending upon whether vasodilation from activation of central alpha 2a receptors or vasoconstriction from activation of peripheral alpha 2b receptors predominates.</p><p>The sedative response is variable and may be due to unidentified patient characteristics, pharmacokinetics, and genetic polymorphisms [<a href="#rid44">44</a>].</p><p>There are no specific guidelines for modifying the dose for older adults or patients who have renal or hepatic impairment. It is prudent to start at the low end of the dose range and titrate slowly based upon the patient's response.</p><p>Abrupt cessation from <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> should be avoided in patients receiving prolonged infusions as this can lead to withdrawal symptoms (eg, agitation, delirium, tachycardia, elevated systolic blood pressure). Management of withdrawal is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Discontinuation'</a>.)</p><p class="headingAnchor" id="H971141"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Potential adverse events during sedation with <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> include hypotension [<a href="#rid45">45</a>], hypertension, nausea, bradycardia [<a href="#rid45">45</a>], and atrial fibrillation. While bradycardia and hypotension can be seen with loading doses and during maintenance, hypertension can also been seen, especially during loading [<a href="#rid46">46-51</a>]. In addition, hypotension is most common during rapid dose escalation.</p><p>Rare cases of refractory cardiogenic shock [<a href="#rid52">52</a>] and fever or hyperthermia have also been reported [<a href="#rid53">53-55</a>].</p><p class="headingAnchor" id="H971148"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> is metabolized by glucuronidation and CYP, clinically important CYP-mediated drug interactions have not been identified. Drugs that lower systemic blood pressure may enhance dexmedetomidine's hypotensive effect while drugs that increase systemic blood pressure may enhance dexmedetomidine's hypertensive effect. Similarly, agents that slow the heart rate may also enhance the bradycardia-inducing effects of dexmedetomidine and may need dose-adjustment during the infusion.</p><p class="headingAnchor" id="H2"><span class="h1">BENZODIAZEPINES</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">Midazolam</a> and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> are the benzodiazepines best suited for sedation in the intensive care unit (ICU) because they can be administered by either intermittent or continuous infusion and have a relatively short duration of effect. Intravenous (IV) <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> is used less often to sedate patients in the ICU. It can be administered by intermittent, but not continuous infusion.</p><p class="headingAnchor" id="H3"><span class="h2">Mechanism</span><span class="headingEndMark"> — </span>Benzodiazepines bind to specific receptors in the gamma-aminobutyric acid (GABA) receptor complex, which enhances the binding of this inhibitory neurotransmitter [<a href="#rid56">56</a>]. Anxiolysis is achieved at low doses. Higher doses are associated with sedation, muscle relaxation, anterograde amnesia, anticonvulsant effects, and both respiratory and cardiovascular depression. Coadministration with an opioid analgesic may potentiate respiratory and cardiovascular depression.</p><p>Benzodiazepines are effective anxiolytics but increase the risk of delirium (see <a class="local">'Adverse effects'</a> below), may prolong mechanical ventilation, and result in excess sedation for prolonged periods due to metabolite storage in adipose tissue. Their efficacy compared with <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> and <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Dexmedetomidine'</a> and  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Propofol'</a>.)</p><p>Benzodiazepines are generally first-line agents for treating alcohol withdrawal. Further details on this indication are also provided separately. (See  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes", section on 'Treatment of psychomotor agitation'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Properties</span><span class="headingEndMark"> — </span>The benzodiazepines differ in potency, rapidity of action, and duration of effect.</p><p class="bulletIndent1"><span class="glyph">●</span>Potency – A benzodiazepine's potency is determined by its binding affinity for the GABA receptor. <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">Lorazepam</a> has the highest binding affinity and the greatest potency. <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">Midazolam</a> and <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> have progressively lower binding affinities and potencies [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapidity of action – A benzodiazepine's rapidity of action is related to how quickly it crosses the blood-brain barrier. <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">Midazolam</a> and <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> readily cross the blood-brain barrier because they are the highly lipophilic. Midazolam has an onset of action of two to five minutes following IV infusion, and diazepam has a nearly immediate onset of action. <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">Lorazepam</a> is less lipophilic and, therefore, has a slower onset of action of 5 to 20 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration of effect – Initially, lipophilic benzodiazepines have a short duration of effect because there is rapid redistribution from the central nervous system (CNS) to peripheral tissue sites. With repeated dosing, however, all benzodiazepines accumulate in adipose tissue, which increases the duration of effect. Patients with obesity may store more drug than patients who are lean and are at greater risk for prolonged benzodiazepine effects. The duration of effect is also influenced by the presence of active metabolites, patient factors (ie, age, body weight, hepatic function, renal function), drug interactions, and mechanism of metabolism.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">Lorazepam</a> has a moderate duration of effect (six to eight hours) when it is administered short-term (&lt;48 hours) by intermittent infusion. This duration of effect reflects lorazepam's low hepatic clearance, small volume of distribution, and absence of active metabolites [<a href="#rid58">58</a>]. Lorazepam is a good choice for longer-term sedation because it has a low risk of drug interactions and its metabolism does not form active metabolites [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">Midazolam</a> has a short duration of effect (two to four hours) when it is given short-term (&lt;48 hours) by intermittent infusion to a patient with intact hepatic function because it has rapid hepatic clearance and there is rapid redistribution to peripheral tissue sites. Midazolam may cause prolonged sedation if it is administered over a longer duration because it has a large volume of distribution, binds to peripheral tissues, and has an active metabolite (alpha-hydroxymidazolam) [<a href="#rid60">60</a>]. The active metabolite is most likely to accumulate in patients who have poor hepatic or renal function or who are receiving medications that inhibit cytochrome P450 (CYP) 3A4 metabolism (eg, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, macrolide antibiotics, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">Diazepam</a> has a short duration of effect (30 to 60 minutes) when it is administered short-term (&lt;48 hours) by intermittent infusion. This duration of effect reflects diazepam's rapid redistribution to peripheral tissue sites and hepatic clearance. Diazepam may cause prolonged sedation with repeated dosing because it has a large volume of distribution and it has two active metabolites (desmethyldiazepam and methyloxazepam). These active metabolites are most likely to accumulate in older adults, patients who have obesity, or patients with renal or hepatic dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tolerance – The need for an increased dose to achieve the same effect with continued administration (ie, tolerance) occurs with all benzodiazepines. It may reflect changes in the volume of distribution or in the density, binding affinity, and/or occupancy of the benzodiazepine receptor.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span>For sedation in the ICU, most benzodiazepines are administered intravenously. Typical dose regimens for <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, and <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> are listed in the table  (<a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">table 1</a>). Dosing for patients with obesity is described separately. (See  <a class="medical medical_review" href="/z/d/html/584.html" rel="external">"Intensive care unit management of patients with obesity"</a>.)</p><p>A loading dose is not commonly administered unless needed during more emergent situations. The typical infusion dosing varies depending upon the benzodiazepine used.</p><p>Patients with suspected tolerance, defined as needing increasing doses over time with episodic agitation episodes (ie, tachyphylaxis), may need to be gradually weaned off the benzodiazepine. Patients who remain sedated on stable doses may do well with abrupt discontinuation of the benzodiazepine ("auto-wean"). Oral agents may facilitate weaning from IV administration. Suggested approaches to weaning are described separately. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Discontinuation'</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Adverse effects</span></p><p class="headingAnchor" id="H91918874"><span class="h4">General</span><span class="headingEndMark"> — </span>Respiratory and cardiovascular depression are well-known dose-dependent complications of benzodiazepines.</p><p>Excess sedation due to the accumulation of drug in adipose tissue can also occur with benzodiazepine-related sedation. Pharmacokinetically, this is more likely among patients who are sedated with benzodiazepines for prolonged periods (eg, &gt;48 hours) or on continuous infusions [<a href="#rid61">61</a>].</p><p>Benzodiazepines increase the risk for delirium in critically ill patients [<a href="#rid62">62-68</a>]. Three studies indicated that the administration of <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a> resulted in a higher prevalence of delirium compared with <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a> (MIDEX: visual assessment scale score difference of 19.7; SEDCOM: 77 versus 54 percent; and MENDS: seven versus three days without delirium or coma) [<a href="#rid45">45,62,69</a>]. Delirium appears to be more common among those who receive deep sedation (even if the deep sedation is for a short duration), are older, or have dementia [<a href="#rid64">64,66</a>].</p><p>Rarely, patients may have a paradoxical reaction to benzodiazepines. This is characterized by agitation, restlessness, and hostility [<a href="#rid70">70</a>]. Increasing the dose may worsen the agitation. The most appropriate management is to discontinue the benzodiazepine and sedate the patient with an alternative sedative. <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">Flumazenil</a> has been reported to reverse the paradoxical reaction [<a href="#rid71">71,72</a>].</p><p>IV <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> may increase the risk of venous thrombosis and phlebitis at the injection site [<a href="#rid73">73</a>]. The latter can cause injection site pain.</p><p class="headingAnchor" id="H8"><span class="h4">Propylene glycol toxicity</span><span class="headingEndMark"> — </span>Propylene glycol is the carrier (solvent) that is used to administer IV <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> or <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a>. Infusion of either drug may be complicated by propylene glycol toxicity [<a href="#rid74">74-77</a>]. However, since diazepam infusions are rarely administered, it is classically seen with high-dose lorazepam infusions. Propylene glycol is not the solvent for IV <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>. Therefore, patients who receive IV midazolam are not at risk for propylene glycol toxicity.</p><p>Propylene glycol toxicity is characterized by hyperosmolarity and an anion gap metabolic acidosis, which is often accompanied by acute kidney injury and can progress to multisystem organ failure, if severe [<a href="#rid74">74-77</a>]. While it can occur with normal doses in patients with normal renal function, it is usually associated with doses above the recommended range of 0.1 mg/kg/hour and/or renal impairment [<a href="#rid76">76,78,79</a>]. An osmolar gap &gt;10 mmol/L suggests that the serum propylene glycol concentration is high enough to cause toxicity [<a href="#rid80">80</a>]. Treatment consists of discontinuing the offending agent and, if severe, initiating dialysis [<a href="#rid77">77,81</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>Numerous drugs used commonly in the ICU may interact with benzodiazepines. Some increase the benzodiazepine effect while others decrease the effect.</p><p>CNS and respiratory depressants (eg, opioids) enhance the CNS and respiratory depressant effect of benzodiazepines. Conversely, CNS stimulants (eg, <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>) decrease the CNS depressant effect of benzodiazepines. Many other drug interactions are related to the metabolism of benzodiazepines via the CYP system:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">Midazolam</a> is susceptible to interactions with drugs that either inhibit or induce CYP3A4 since CYP3A4 hydroxylates midazolam to two active metabolites, 1-hydroxy-midazolam and 3-hydroxy-midazolam. As examples, the azole antifungals (eg, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>) and the macrolides and related antibiotics (eg, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>) may prolong midazolam activity by inhibiting CYP3A4. Conversely, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> may decrease midazolam activity by inducing CYP3A4. Rifamycins (eg, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>) may decrease midazolam activity by increasing CYP-mediated oxidative metabolism. Hydantoins (eg, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">fosphenytoin</a>) may increase midazolam clearance and midazolam inhibits hydantoin clearance; the latter leads to increased serum concentrations of the hydantoins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">Diazepam</a> is susceptible to interactions with many of the same drugs that inhibit or induce CYP because it is hydroxylated by CYP3A4 to <a class="drug drug_general" data-topicid="9973" href="/z/d/drug information/9973.html" rel="external">temazepam</a> and N-demethylated by CYP3A4 and CYP2C19 to desmethyldiazepam. Temazepam and desmethyldiazepam are active metabolites that are subsequently metabolized to another active metabolite, <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">oxazepam</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">Lorazepam</a> does not interact with drugs that inhibit or induce CYP because it undergoes extensive glucuronidation in the liver to an inactive 3-O-phenolic metabolite.</p><p></p><p class="headingAnchor" id="H4071906664"><span class="h1">ANTIPSYCHOTICS</span><span class="headingEndMark"> — </span>Antipsychotics (typical and atypical) are dopamine antagonists but have an unclear mechanism of action. They can be used intermittently as supplements to other agents in the intensive care unit (ICU) for the treatment of delirium. <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">Haloperidol</a>, a typical antipsychotic, was frequently used in the past but use has declined since data are not supportive of routine use for delirium prevention. Data also suggest a similar limited role for atypical antipsychotics. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Delirium'</a>.)</p><p class="headingAnchor" id="H3414187600"><span class="h2">Mechanism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">Haloperidol</a> and the other neuroleptics antagonize dopamine and other neurotransmitters. However, their precise mechanism of action remains unknown. Haloperidol lactate can be administered intravenously, has a mild sedative effect, and has relatively low cardiorespiratory depressive effects. It is primarily used as a supplement to sedation when delirium is thought to be the main driver of agitation.</p><p>Atypical antipsychotics (<a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a>) are oral agents that may also be used for similar indications (eg, nocturnal delirium, interfering with sleep).</p><p class="headingAnchor" id="H1477261372"><span class="h2">Properties</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">Haloperidol</a> causes dose-dependent sedation. It tends to be less sedating and has less anticholinergic activity than other neuroleptics.</p><p class="bulletIndent1"><span class="glyph">●</span>Rapidity of onset – <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">Haloperidol</a> has an onset of action 5 to 20 minutes after intravenous (IV) infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration of effect – <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">Haloperidol</a>'s duration of effect varies and depends upon the cumulative dose. In general, redosing may be needed 4 to 12 hours after symptoms have been controlled with the initial doses.</p><p></p><p><a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">Haloperidol</a> is highly protein bound, has a large volume of distribution, and is metabolized hepatically by cytochrome P450 (CYP) 3A4, CYP2D6, and glucuronidation; the hydroxymetabolite (reduced haloperidol) is active [<a href="#rid82">82</a>]. The pyridinium metabolite may be neurotoxic [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H1421219079"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span>The IV route is the most common route used to administer <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> in the ICU. However, IV use has not been approved by the US Food and Drug Administration (FDA) due to the greater risk of serious adverse events compared with oral or intramuscular administration, most notably torsades de pointes and sudden cardiac death [<a href="#rid84">84</a>].</p><p>Dosing regimens ranging from 1 to 2 mg IV every six hours to 0.5 to 2 mg/hour IV infusion have been used for the prevention of delirium in adult ICU patients, none of which have been validated  (<a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">table 1</a>) [<a href="#rid85">85</a>]. Continuous infusions are rarely indicated, but studies suggest that they are probably safe and effective [<a href="#rid86">86-88</a>]. Typical initial regimens range from 1.25 to 5 mg IV bolus repeated every 8 to 12 hours depending on age and cardiovascular risk factors; subsequent doses may be repeated or titrated to the desired response to a maximum dose of 20 to 40 mg in 24 hours [<a href="#rid89">89-92</a>]. In a survey of 250 pharmacists, the most frequently cited daily IV dose range was 5 to 10 mg, although 8 percent of respondents cited daily IV doses of ≥21 mg [<a href="#rid93">93</a>].</p><p>The safe maximum daily dose of <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> is not known. There are case reports of doses as high as 945 mg/day [<a href="#rid86">86,94</a>]. Doses greater than 200 mg/day have been safely administered for up to 15 consecutive days [<a href="#rid86">86,95</a>].</p><p>We use antipsychotics (typical and atypical) with caution in all older adults with dementia, including the critically ill, since they carry an increased risk of cardiovascular death. (See <a class="local">'Adverse effects'</a> below.)</p><p class="headingAnchor" id="H1778906341"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Haloperidol-associated polymorphic ventricular tachycardia (including torsades de pointes) is an uncommon but severe adverse reaction [<a href="#rid96">96,97</a>]. It is primarily associated with intermittent high-dose IV administration and a prolonged corrected QT (QTc) interval. A prolonged QTc interval has also been described in patients taking atypical antipsychotics [<a href="#rid98">98</a>]. When intermittent <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> infusions or atypical antipsychotics are used, the QTc interval on electrocardiogram (EKG) should be monitored daily for the first two to three days. This is also advisable when the dose of these drugs is increased or when other QTc-prolonging meds are coadministered. If the QTc interval does not prolong, ongoing telemonitoring is sufficient to detect a relative change and prompt quantitation by EKG. Haloperidol and other antipsychotics should not be given if the QTc interval exceeds 500 msec. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p>Other potential side effects of <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> include acute dystonic reactions, parkinsonism, tardive dyskinesia, akathisia, and neuroleptic malignant syndrome. For unclear reasons, extrapyramidal side effects are less common among patients receiving IV haloperidol than among those receiving oral haloperidol [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">"Treatment of dystonia in children and adults"</a>.)</p><p>Older adults with dementia may have an increased risk of cardiovascular-related death (due to heart failure or sudden cardiac death) or infection-related death (due to pneumonia) when treated with atypical antipsychotics. This was illustrated by a meta-analysis of 15 randomized trials (5204 patients) that found that older patients with dementia who were treated with atypical antipsychotics had an increased risk of death compared with those who received placebo (3.5 versus 2.2 percent; odds ratio 1.54, 95% CI 1.06-2.23) [<a href="#rid100">100</a>]. These findings were supported by two subsequent studies [<a href="#rid101">101,102</a>]. The FDA has since issued a black box warning for the atypical antipsychotics.</p><p class="headingAnchor" id="H2781596314"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">Haloperidol</a> interacts with numerous drugs that are commonly used in the ICU. As an example, drugs with central nervous system (CNS) depressant effects (eg, opioids, sedatives) may enhance the CNS-depressant effect of haloperidol.</p><p>Other drug interactions are related to the metabolism of <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> via the CYP3A4 and CYP2D6 pathways. These include azole antifungals and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic azole antifungals (eg, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>), HIV and HCV protease inhibitors, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, inhibit CYP3A4, which prolongs <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> increases CYP3A4 metabolism, which decreases <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> activity. This effect is enhanced because haloperidol increases carbamazepine activity by inhibiting carbamazepine metabolism.</p><p></p><p>The rifamycins (eg, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a>) also induce CYP-mediated oxidative metabolism and decrease <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> activity. Anticholinergics (eg, <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a>) increase haloperidol clearance via an unknown mechanism.</p><p>When <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> is used, other drugs that enhance the QTc-prolonging effect of haloperidol should be avoided (eg, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, high-dose <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>, <a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">domperidone</a>, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>, fluoroquinolone antibiotics, tricyclic antidepressants, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>). Additional agents are listed in the table  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 2</a>). <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">Metoclopramide</a> may increase haloperidol toxicity and should also not be given concurrently.</p><p class="headingAnchor" id="H333125526"><span class="h1">LESS COMMONLY USED AGENTS</span><span class="headingEndMark"> — </span>Barbiturates and <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> are used as last resort or adjunctive agents when first-line agents have failed.</p><p class="headingAnchor" id="H75560944"><span class="h2">Barbiturates</span><span class="headingEndMark"> — </span>Very limited data support the use of <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> to sedate mechanically ventilated adult intensive care unit (ICU) patients [<a href="#rid103">103</a>].</p><p><a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a> binds to gamma-aminobutyric acid (GABA) 2 receptors, increasing the duration of GABA-gated chloride channel opening.</p><p><a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a> commonly causes hypotension and may produce profound cardiovascular and respiratory depression. Other undesirable characteristics of phenobarbital include prolonged elimination half-life, induction of the cytochrome P450 (CYP) enzyme system, and accumulation of drugs in renal and hepatic dysfunction.</p><p class="headingAnchor" id="H2697731289"><span class="h2">Ketamine</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> as an adjunctive analgo-sedative in mechanically ventilated patients has resurged since the start of coronavirus disease 2019 (COVID-19) pandemic when it was needed as a second or third-line agent for sedation in the ICU [<a href="#rid104">104,105</a>]. With sedative and analgesic properties, ketamine may reduce opioid requirements [<a href="#rid106">106</a>].</p><p><a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> is approved by the US Food and Drug Administration (FDA) as an anesthetic agent for diagnostic and surgical procedures. Off-label uses include procedural sedation/analgesia, treatment of extreme agitation, and treatment of mood disorders; it can also be used as an adjunct to opioid analgesia as well as to manage opioid tolerance, withdrawal, hyperalgesia, or neuropathic pain [<a href="#rid107">107-110</a>].</p><p><a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> is a parenteral anesthetic agent with analgesic and bronchodilator properties in subanesthetic doses. Ketamine, a phencyclidine derivative, noncompetitively blocks glutamate N-methyl-D-aspartate (NMDA) receptors within sensory nerve endings; other pharmacologic actions at subanesthetic doses have been identified, including opioid and muscarinic agonist activities and nicotinic receptor blockade [<a href="#rid111">111</a>].</p><p>Due to its lipid solubility, an intravenous bolus dose of <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> is active within one minute with a duration of action of 10 to 15 minutes. Ketamine is metabolized in the liver through CYP systems to several metabolites, including the weakly active metabolite norketamine, that are cleared by the kidneys.</p><p><a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> produces a "dissociated anesthesia," wherein patients remain conscious with spontaneous breathing and intact brain stem reflexes. By stimulating the sympathetic nervous system, there is less cardiovascular depression; this preserves and sometimes increases blood pressure, making it an attractive agent for use in patients in shock or with frank hypotension. Ketamine also has mild bronchodilatory activity such that it has been anecdotally used for sedation in patients with status asthmaticus. The value of anesthetic agents in this population is provided separately. (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Anesthetic agents'</a>.)</p><p><a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">Ketamine</a> side effects include adverse psychoactive effects (eg, vivid hallucinations, confusion, and delirium), hemodynamic instability, excessive salivation, and respiratory and cardiac depression. Ketamine is contraindicated in patients with known hypersensitivity to it and in patients at risk from potentially significant elevations in blood pressure. Cholestatic liver injury has been reported following prolonged high-dose ketamine administration in critically ill patients with COVID-19 [<a href="#rid112">112,113</a>]. Ketamine plasma concentrations producing analgesia are typically lower than concentrations producing psychomimetic effects (eg, hallucinations, confusion, nightmares) [<a href="#rid114">114,115</a>].</p><p>FDA-approved anesthesia dosing and administration for <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> are shown on the table  (<a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">table 1</a>). There are no standard recommendations regarding dosing for analgo-sedation in mechanically ventilated critically ill patients. Reported regimens include a 0.1 to 0.5 mg/kg bolus followed by an initiation of a 0.2 to 0.5 mg/kg/hour continuous infusion then titrated to pain and sedation goal with a typical maintenance infusion of 0.04 to 2.5 mg/kg/hour. Higher median hourly doses are reported for analgo-sedation in mechanically ventilated patients with COVID-19-related acute respiratory distress syndrome [<a href="#rid104">104,105,116</a>].</p><p class="headingAnchor" id="H99696769"><span class="h1">INVESTIGATIONAL AGENTS</span></p><p class="headingAnchor" id="H27695579"><span class="h2">Sevoflurane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">Sevoflurane</a>, a polyfluorinated methyl-isopropyl compound, is a volatile inhalational anesthetic that is being evaluated as a potential sedative agent for intensive care unit (ICU) patients. Further study and clinician education will be required before sevoflurane can be used as a routine sedative in critically ill patients.</p><p>Ninety-five to 98 percent of <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">sevoflurane</a> is eliminated through the lungs while the remaining 2 to 5 percent undergoes rapid hepatic metabolism to inorganic fluoride and hexafluoroisopropanol (HFIP) [<a href="#rid117">117</a>]. HFIP in the blood is conjugated by glucuronic acid and then secreted by the kidneys.</p><p>Potential advantages of <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">sevoflurane</a> as a sedating agent for critically ill ICU patients include the short duration of action and rapid elimination [<a href="#rid118">118</a>]. Potential disadvantages include fluoride accumulation with prolonged use (especially in patients with impaired renal function) and malignant hyperthermia [<a href="#rid118">118</a>]. Additionally, sevoflurane undergoes degradation on contact with alkaline carbon dioxide absorbents used to remove carbon dioxide from the circuit, becoming a potentially nephrotoxic product (trifluoromethyl vinyl ether; compound A) [<a href="#rid117">117</a>]. (See  <a class="medical medical_review" href="/z/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis"</a> and  <a class="medical medical_review" href="/z/d/html/403.html" rel="external">"Susceptibility to malignant hyperthermia: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H2448803487"><span class="h2">Baclofen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">Baclofen</a> is a gamma-aminobutyric acid (GABA) type B receptor agonist that at high levels can reduce consciousness. Preliminary evidence describes its use in critically ill patients, but further studies are needed before baclofen can be recommended for use in individuals with agitation. This evidence is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Investigational agents'</a>.)</p><p class="headingAnchor" id="H4113307292"><span class="h2">Ciprofol</span><span class="headingEndMark"> — </span>Ciprofol is a phenol derivative of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> with increased stereoselective effects adding to its anesthetic properties [<a href="#rid119">119,120</a>]. The therapeutic index of ciprofol is 1.5 times that of propofol and its potency is four- to fivefold higher. Early phase II trials suggest noninferior efficacy and safety profile when compared with propofol [<a href="#rid121">121</a>].</p><p class="headingAnchor" id="H725422894"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120246.html" rel="external">"Society guideline links: Nonprocedural sedation"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – Distress due to pain, fear, anxiety, dyspnea, or delirium is common among critically ill patients in the intensive care unit (ICU). Distress may cause ventilator asynchrony and increase sympathetic tone, which may have untoward clinical effects. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agent selection</strong> – No sedative-analgesic agent is sufficiently superior to other agents to warrant its use in all clinical situations. As a result, selection of an agent must be individualized according to pharmacokinetic variables (eg, potential interactions with other drugs) and nonpharmacokinetic variables (eg, renal and liver failure, presence of bradycardia or hypotension), the etiology of the distress, and the desired depth of sedation. Selecting an agent is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Selection of agent(s)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classes of agents</strong> – Several classes of agent are available and most often used in combination  (<a class="graphic graphic_table graphicRef79667" href="/z/d/graphic/79667.html" rel="external">table 1</a>). The most common agents used for sedation are the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opioid analgesics</strong> – <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">Fentanyl</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, and <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> sulphate are the most commonly used intravenous (IV) opioids to manage distress due to pain in critically ill patients. Nonopioid agents can also be used (eg, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, nonsteroidal anti-inflammatory agents). Choice of opioid analgesic and their individual properties are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient", section on 'Opioid analgesics'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">Propofol</a> – Propofol is an IV anesthetic that activates central gamma-aminobutyric acid (GABA) type A receptors. Propofol has a rapid onset and short duration of effect. Propofol has amnesic, anxiolytic, anticonvulsant, and muscle relaxant (including bronchodilation) effects. Hypotension is the most common adverse effect while hypertriglyceridemia, pancreatitis, and propofol-related infusion syndrome (PRIS) are more serious complications. (See <a class="local">'Propofol'</a> above.)</p><p></p><p class="bulletIndent2">PRIS is a rare complication of <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>. PRIS should be suspected in patients on high doses or a prolonged infusion of propofol who develop unexplained arrythmia, instability, acidosis, electrolyte disturbance, transaminitis, or acute kidney injury. When PRIS is suspected, work up includes obtaining a serum lactate creatinine kinase, and myoglobin. Patients who have PRIS require prompt discontinuation of the propofol infusion since PRIS-related mortality is high (33 to 66 percent). (See <a class="local">'Propofol-related infusion syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">Dexmedetomidine</a> – Dexmedetomidine is a highly selective, centrally acting alpha-2-agonist with anxiolytic, sedative, and some analgesic effects. Dexmedetomidine has an onset of action of approximately 15 to 20 minutes and an elimination half-life of two to three hours, longer in those who are critically ill and on continuous infusions. The main adverse effects are hypotension and bradycardia, although hypertension and atrial fibrillation may be seen less commonly. (See <a class="local">'Dexmedetomidine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benzodiazepines</strong> – Benzodiazepines are GABA receptor agonists. <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">Midazolam</a> and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> are the most common benzodiazepines that are administered by either intermittent or continuous infusion and have a relatively short duration of effect. They are effective anxiolytics but can also induce muscle relaxation and retrograde amnesia and have anticonvulsant effects. However, benzodiazepines, when administered for long periods as an infusion (eg, &gt;48 hours), can have a prolonged sedative effect due to metabolite storage in adipose tissue and can increase the risk of delirium compared with other agents, such as <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> and <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">dexmedetomidine</a>. Respiratory and cardiovascular depression are well-known, common, dose-dependent complications of benzodiazepines. Propylene glycol toxicity is a rare complication of high-dose lorazepam infusions that requires immediate cessation of the drug. (See <a class="local">'Benzodiazepines'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antipsychotics</strong> – Antipsychotics (typical [<a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>] and atypical [<a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a>]) are dopamine antagonists that can be used intermittently as supplements to other sedative agents in the ICU for the treatment of delirium. IV haloperidol is not approved by the US Food and Drug Administration for the treatment of delirium, thus, IV administration for this indication is off-label. A prolonged corrected QT interval with consequent precipitation of ventricular arrythmias is the most worrisome adverse effect of antipsychotics. (See <a class="local">'Antipsychotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Others</strong> – <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a> and <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> are less commonly used. Phenobarbital is a GABA2 agonist that can cause profound cardiac and respiratory depression. Ketamine is an anesthetic agent that blocks glutamate N-methyl-D-aspartate (NMDA) receptors and has some analgo-sedative properties; adverse reactions include vivid hallucinations, confusion, and delirium as well as hemodynamic instability, excessive salivation, and respiratory and cardiac depression. (See <a class="local">'Barbiturates'</a> above and <a class="local">'Ketamine'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med 2018; 46:e825.</a></li><li><a class="nounderline abstract_t">Nelson LE, Guo TZ, Lu J, et al. The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci 2002; 5:979.</a></li><li><a class="nounderline abstract_t">Deambrogio V, Gatti G, Mongio F, et al. [A case of superficial lymph node tuberculosis]. Minerva Med 1991; 82:507.</a></li><li><a class="nounderline abstract_t">Zecharia AY, Nelson LE, Gent TC, et al. The involvement of hypothalamic sleep pathways in general anesthesia: testing the hypothesis using the GABAA receptor beta3N265M knock-in mouse. J Neurosci 2009; 29:2177.</a></li><li><a class="nounderline abstract_t">Jurd R, Arras M, Lambert S, et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. FASEB J 2003; 17:250.</a></li><li><a class="nounderline abstract_t">Asserhøj LL, Mosbech H, Krøigaard M, Garvey LH. No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut†. Br J Anaesth 2016; 116:77.</a></li><li><a class="nounderline abstract_t">Dziedzic A. Is Propofol Safe For Food Allergy Patients? A Review of the Evidence. SAAD Dig 2016; 32:23.</a></li><li><a class="nounderline abstract_t">Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995; 50:636.</a></li><li><a class="nounderline abstract_t">Carrasco G, Molina R, Costa J, et al. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. Chest 1993; 103:557.</a></li><li><a class="nounderline abstract_t">Kress JP, O'Connor MF, Pohlman AS, et al. Sedation of critically ill patients during mechanical ventilation. A comparison of propofol and midazolam. Am J Respir Crit Care Med 1996; 153:1012.</a></li><li><a class="nounderline abstract_t">Riker RR, Glisic EK, Fraser GL. Propofol infusion syndrome: difficult to recognize, difficult to study. Crit Care Med 2009; 37:3169.</a></li><li><a class="nounderline abstract_t">Corrado MJ, Kovacevic MP, Dube KM, et al. The Incidence of Propofol-Induced Hypertriglyceridemia and Identification of Associated Risk Factors. Crit Care Explor 2020; 2:e0282.</a></li><li><a class="nounderline abstract_t">Witenko CJ, Littlefield AJ, Abedian S, et al. The Safety of Continuous Infusion Propofol in Mechanically Ventilated Adults With Coronavirus Disease 2019. Ann Pharmacother 2022; 56:5.</a></li><li><a class="nounderline abstract_t">Pancholi P, Wu J, Lessen S, et al. Triglyceride Concentrations and Their Relationship to Sedation Choice and Outcomes in Mechanically Ventilated Patients Receiving Propofol. Ann Am Thorac Soc 2023; 20:94.</a></li><li class="breakAll">Diprivan package insert. Astra Zeneca. August 2005.</li><li><a class="nounderline abstract_t">Hug CC Jr, McLeskey CH, Nahrwold ML, et al. Hemodynamic effects of propofol: data from over 25,000 patients. Anesth Analg 1993; 77:S21.</a></li><li><a class="nounderline abstract_t">Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995; 333:147.</a></li><li><a class="nounderline abstract_t">Mirenda J. Prolonged propofol sedation in the critical care unit. Crit Care Med 1995; 23:1304.</a></li><li><a class="nounderline abstract_t">Blakey SA, Hixson-Wallace JA. Clinical significance of rare and benign side effects: propofol and green urine. Pharmacotherapy 2000; 20:1120.</a></li><li><a class="nounderline abstract_t">Nates J, Avidan A, Gozal Y, Gertel M. Appearance of white urine during propofol anesthesia. Anesth Analg 1995; 81:210.</a></li><li><a class="nounderline abstract_t">Ho KM, Ng JY. The use of propofol for medium and long-term sedation in critically ill adult patients: a meta-analysis. Intensive Care Med 2008; 34:1969.</a></li><li><a class="nounderline abstract_t">Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth 2019; 122:448.</a></li><li><a class="nounderline abstract_t">Crozier TA. The 'propofol infusion syndrome': myth or menace? Eur J Anaesthesiol 2006; 23:987.</a></li><li><a class="nounderline abstract_t">Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia 2007; 62:690.</a></li><li><a class="nounderline abstract_t">Fong JJ, Sylvia L, Ruthazer R, et al. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med 2008; 36:2281.</a></li><li><a class="nounderline abstract_t">McKeage K, Perry CM. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs 2003; 17:235.</a></li><li><a class="nounderline abstract_t">Pothineni NV, Hayes K, Deshmukh A, Paydak H. Propofol-related infusion syndrome: rare and fatal. Am J Ther 2015; 22:e33.</a></li><li><a class="nounderline abstract_t">Wong JM. Propofol infusion syndrome. Am J Ther 2010; 17:487.</a></li><li><a class="nounderline abstract_t">Diedrich DA, Brown DR. Analytic reviews: propofol infusion syndrome in the ICU. J Intensive Care Med 2011; 26:59.</a></li><li><a class="nounderline abstract_t">Culp KE, Augoustides JG, Ochroch AE, Milas BL. Clinical management of cardiogenic shock associated with prolonged propofol infusion. Anesth Analg 2004; 99:221.</a></li><li><a class="nounderline abstract_t">Fudickar A, Bein B. Propofol infusion syndrome: update of clinical manifestation and pathophysiology. Minerva Anestesiol 2009; 75:339.</a></li><li><a class="nounderline abstract_t">Casserly B, O'Mahony E, Timm EG, et al. Propofol infusion syndrome: an unusual cause of renal failure. Am J Kidney Dis 2004; 44:e98.</a></li><li><a class="nounderline abstract_t">Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care 2009; 13:R169.</a></li><li><a class="nounderline abstract_t">Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med 2009; 37:3024.</a></li><li><a class="nounderline abstract_t">Branca D, Roberti MS, Vincenti E, Scutari G. Uncoupling effect of the general anesthetic 2,6-diisopropylphenol in isolated rat liver mitochondria. Arch Biochem Biophys 1991; 290:517.</a></li><li><a class="nounderline abstract_t">Rigoulet M, Devin A, Avéret N, et al. Mechanisms of inhibition and uncoupling of respiration in isolated rat liver mitochondria by the general anesthetic 2,6-diisopropylphenol. Eur J Biochem 1996; 241:280.</a></li><li><a class="nounderline abstract_t">De Kock M, Crochet B, Morimont C, Scholtes JL. Intravenous or epidural clonidine for intra- and postoperative analgesia. Anesthesiology 1993; 79:525.</a></li><li><a class="nounderline abstract_t">Omote K, Kitahata LM, Collins JG, et al. Interaction between opiate subtype and alpha-2 adrenergic agonists in suppression of noxiously evoked activity of WDR neurons in the spinal dorsal horn. Anesthesiology 1991; 74:737.</a></li><li><a class="nounderline abstract_t">Poonai N, Spohn J, Vandermeer B, et al. Intranasal Dexmedetomidine for Procedural Distress in Children: A Systematic Review. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clin Pharmacokinet 2017; 56:893.</a></li><li><a class="nounderline abstract_t">Dutta S, Lal R, Karol MD, et al. Influence of cardiac output on dexmedetomidine pharmacokinetics. J Pharm Sci 2000; 89:519.</a></li><li><a class="nounderline abstract_t">Iirola T, Aantaa R, Laitio R, et al. Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. Crit Care 2011; 15:R257.</a></li><li><a class="nounderline abstract_t">Dasta JF, Kane-Gill SL, Durtschi AJ. Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data. Ann Pharmacother 2004; 38:1130.</a></li><li><a class="nounderline abstract_t">Holliday SF, Kane-Gill SL, Empey PE, et al. Interpatient variability in dexmedetomidine response: a survey of the literature. ScientificWorldJournal 2014; 2014:805013.</a></li><li><a class="nounderline abstract_t">Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012; 307:1151.</a></li><li><a class="nounderline abstract_t">Lewis K, Alshamsi F, Carayannopoulos KL, et al. Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials. Intensive Care Med 2022; 48:811.</a></li><li><a class="nounderline abstract_t">Ebert TJ, Hall JE, Barney JA, et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93:382.</a></li><li><a class="nounderline abstract_t">Gerlach AT, Dasta JF, Steinberg S, et al. A new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients. J Crit Care 2009; 24:568.</a></li><li><a class="nounderline abstract_t">Gerlach AT, Blais DM, Jones GM, et al. Predictors of dexmedetomidine-associated hypotension in critically ill patients. Int J Crit Illn Inj Sci 2016; 6:109.</a></li><li><a class="nounderline abstract_t">Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med 2010; 36:926.</a></li><li><a class="nounderline abstract_t">Zhang X, Wang R, Lu J, et al. Effects of different doses of dexmedetomidine on heart rate and blood pressure in intensive care unit patients. Exp Ther Med 2016; 11:360.</a></li><li><a class="nounderline abstract_t">Sichrovsky TC, Mittal S, Steinberg JS. Dexmedetomidine sedation leading to refractory cardiogenic shock. Anesth Analg 2008; 106:1784.</a></li><li class="breakAll">PRECEDEXTM (dexmedetomidine hydrochloride) injection, for
intravenous use. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021038s031s033lbl.pdf (Accessed on September 13, 2022).</li><li><a class="nounderline abstract_t">Peterson J, Thomas W, Michaud C, Parker J. Incidence of Fever Associated With Dexmedetomidine in the Adult Intensive Care Unit. J Pharm Pract 2022; 35:716.</a></li><li><a class="nounderline abstract_t">Schurr JW, Ambrosi L, Lastra JL, et al. Fever Associated With Dexmedetomidine in Adult Acute Care Patients: A Systematic Review of the Literature. J Clin Pharmacol 2021; 61:848.</a></li><li><a class="nounderline abstract_t">Möhler H, Richards JG. The benzodiazepine receptor: a pharmacological control element of brain function. Eur J Anaesthesiol Suppl 1988; 2:15.</a></li><li><a class="nounderline abstract_t">Arendt RM, Greenblatt DJ, deJong RH, et al. In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther 1983; 227:98.</a></li><li><a class="nounderline abstract_t">Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981; 6:89.</a></li><li><a class="nounderline abstract_t">Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30:119.</a></li><li><a class="nounderline abstract_t">Ziegler WH, Schalch E, Leishman B, Eckert M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol 1983; 16 Suppl 1:63S.</a></li><li><a class="nounderline abstract_t">Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest 1998; 114:541.</a></li><li><a class="nounderline abstract_t">Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007; 298:2644.</a></li><li><a class="nounderline abstract_t">Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006; 104:21.</a></li><li><a class="nounderline abstract_t">Jones C, Bäckman C, Capuzzo M, et al. Precipitants of post-traumatic stress disorder following intensive care: a hypothesis generating study of diversity in care. Intensive Care Med 2007; 33:978.</a></li><li><a class="nounderline abstract_t">Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004; 291:1753.</a></li><li><a class="nounderline abstract_t">Pisani MA, Murphy TE, Araujo KL, et al. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med 2009; 37:177.</a></li><li><a class="nounderline abstract_t">Zaal IJ, Devlin JW, Hazelbag M, et al. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med 2015; 41:2130.</a></li><li><a class="nounderline abstract_t">Zhou Y, Yang J, Wang B, et al. Sequential use of midazolam and dexmedetomidine for long-term sedation may reduce weaning time in selected critically ill, mechanically ventilated patients: a randomized controlled study. Crit Care 2022; 26:122.</a></li><li><a class="nounderline abstract_t">Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301:489.</a></li><li><a class="nounderline abstract_t">Litchfield NB. Complications of Intravenous Diazepam - Adverse Psychological Reactions. (An assessment of 16,000 cases). Anesth Prog 1980; 27:175.</a></li><li><a class="nounderline abstract_t">Thurston TA, Williams CG, Foshee SL. Reversal of a paradoxical reaction to midazolam with flumazenil. Anesth Analg 1996; 83:192.</a></li><li><a class="nounderline abstract_t">Fulton SA, Mullen KD. Completion of upper endoscopic procedures despite paradoxical reaction to midazolam: a role for flumazenil? Am J Gastroenterol 2000; 95:809.</a></li><li class="breakAll">Diazepam injection [Baxter Healthcare Corporation] United States Food and Drug Administration approved prescribing information. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1045 (Accessed on May 12, 2010).</li><li><a class="nounderline abstract_t">Tayar J, Jabbour G, Saggi SJ. Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. N Engl J Med 2002; 346:1253.</a></li><li><a class="nounderline abstract_t">Cawley MJ. Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review. Pharmacotherapy 2001; 21:1140.</a></li><li><a class="nounderline abstract_t">Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest 2005; 128:1674.</a></li><li><a class="nounderline abstract_t">Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam. N Engl J Med 2000; 343:815.</a></li><li><a class="nounderline abstract_t">Arroliga AC, Shehab N, McCarthy K, Gonzales JP. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. Crit Care Med 2004; 32:1709.</a></li><li><a class="nounderline abstract_t">Yahwak JA, Riker RR, Fraser GL, Subak-Sharpe S. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Pharmacotherapy 2008; 28:984.</a></li><li><a class="nounderline abstract_t">Barnes BJ, Gerst C, Smith JR, et al. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy 2006; 26:23.</a></li><li><a class="nounderline abstract_t">Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial 2007; 20:217.</a></li><li><a class="nounderline abstract_t">Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999; 37:435.</a></li><li><a class="nounderline abstract_t">Avent KM, DeVoss JJ, Gillam EM. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites. Chem Res Toxicol 2006; 19:914.</a></li><li class="breakAll">Information for Healthcare Professionals: Haloperidol http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm085203.htm (Accessed on May 12, 2010).</li><li><a class="nounderline abstract_t">Marra A, Vargas M, Buonanno P, et al. Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2021; 25:1582.</a></li><li><a class="nounderline abstract_t">Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 1994; 22:433.</a></li><li><a class="nounderline abstract_t">Fernandez F, Holmes VF, Adams F, Kavanaugh JJ. Treatment of severe, refractory agitation with a haloperidol drip. J Clin Psychiatry 1988; 49:239.</a></li><li><a class="nounderline abstract_t">Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother 1995; 29:690.</a></li><li><a class="nounderline abstract_t">Page VJ, Ely EW, Gates S, et al. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2013; 1:515.</a></li><li><a class="nounderline abstract_t">Girard TD, Exline MC, Carson SS, et al. Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. N Engl J Med 2018; 379:2506.</a></li><li><a class="nounderline abstract_t">Andersen-Ranberg NC, Poulsen LM, Perner A, et al. Haloperidol for the Treatment of Delirium in ICU Patients. N Engl J Med 2022; 387:2425.</a></li><li><a class="nounderline abstract_t">Wang M, Yankama TT, Abdallah GT, et al. A Retrospective Comparison of the Effectiveness and Safety of Intravenous Olanzapine Versus Intravenous Haloperidol for Agitation in Adult Intensive Care Unit Patients. J Intensive Care Med 2022; 37:222.</a></li><li><a class="nounderline abstract_t">Devlin JW, Bhat S, Roberts RJ, Skrobik Y. Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states. Ann Pharmacother 2011; 45:1217.</a></li><li><a class="nounderline abstract_t">Stern TA. The management of depression and anxiety following myocardial infarction. Mt Sinai J Med 1985; 52:623.</a></li><li><a class="nounderline abstract_t">Fish DN. Treatment of delirium in the critically ill patient. Clin Pharm 1991; 10:456.</a></li><li><a class="nounderline abstract_t">Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993; 13:128.</a></li><li><a class="nounderline abstract_t">Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119:391.</a></li><li><a class="nounderline abstract_t">Kram BL, Kram SJ, Brooks KR. Implications of atypical antipsychotic prescribing in the intensive care unit. J Crit Care 2015; 30:814.</a></li><li><a class="nounderline abstract_t">Menza MA, Murray GB, Holmes VF, Rafuls WA. Decreased extrapyramidal symptoms with intravenous haloperidol. J Clin Psychiatry 1987; 48:278.</a></li><li><a class="nounderline abstract_t">Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934.</a></li><li><a class="nounderline abstract_t">Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146:775.</a></li><li><a class="nounderline abstract_t">Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176:627.</a></li><li><a class="nounderline abstract_t">Gagnon DJ, Fontaine GV, Riker RR, Fraser GL. Repurposing Valproate, Enteral Clonidine, and Phenobarbital for Comfort in Adult ICU Patients: A Literature Review with Practical Considerations. Pharmacotherapy 2017; 37:1309.</a></li><li><a class="nounderline abstract_t">Groth CM, Droege CA, Connor KA, et al. Multicenter Retrospective Review of Ketamine Use in the ICU. Crit Care Explor 2022; 4:e0633.</a></li><li><a class="nounderline abstract_t">Pendleton KM, Stephenson LE, Goeden N, et al. Ketamine Infusion for Sedation and Analgesia during Mechanical Ventilation in the ICU: A Multicenter Evaluation. Crit Care Res Pract 2022; 2022:9853344.</a></li><li><a class="nounderline abstract_t">Chan K, Burry LD, Tse C, et al. Impact of Ketamine on Analgosedative Consumption in Critically Ill Patients: A Systematic Review and Meta-Analysis. Ann Pharmacother 2022; 56:1139.</a></li><li><a class="nounderline abstract_t">Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth 2011; 58:911.</a></li><li><a class="nounderline abstract_t">De Pinto M, Jelacic J, Edwards WT. Very-low-dose ketamine for the management of pain and sedation in the ICU. J Opioid Manag 2008; 4:54.</a></li><li><a class="nounderline abstract_t">Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14:145.</a></li><li><a class="nounderline abstract_t">Maher DP, Chen L, Mao J. Intravenous Ketamine Infusions for Neuropathic Pain Management: A Promising Therapy in Need of Optimization. Anesth Analg 2017; 124:661.</a></li><li><a class="nounderline abstract_t">Sawynok J. Topical and peripheral ketamine as an analgesic. Anesth Analg 2014; 119:170.</a></li><li><a class="nounderline abstract_t">Wendel-Garcia PD, Erlebach R, Hofmaenner DA, et al. Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome. Crit Care 2022; 26:148.</a></li><li><a class="nounderline abstract_t">Henrie J, Gerard L, Declerfayt C, et al. Profile of liver cholestatic biomarkers following prolonged ketamine administration in patients with COVID-19. BMC Anesthesiol 2023; 23:44.</a></li><li><a class="nounderline abstract_t">Himmelseher S, Durieux ME. Ketamine for perioperative pain management. Anesthesiology 2005; 102:211.</a></li><li><a class="nounderline abstract_t">Tucker AP, Kim YI, Nadeson R, Goodchild CS. Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain[ISRCTN83088383]. BMC Anesthesiol 2005; 5:2.</a></li><li><a class="nounderline abstract_t">Hurth KP, Jaworski A, Thomas KB, et al. The Reemergence of Ketamine for Treatment in Critically Ill Adults. Crit Care Med 2020; 48:899.</a></li><li><a class="nounderline abstract_t">Behne M, Wilke HJ, Harder S. Clinical pharmacokinetics of sevoflurane. Clin Pharmacokinet 1999; 36:13.</a></li><li><a class="nounderline abstract_t">Bracco D, Donatelli F. Volatile agents for ICU sedation? Intensive Care Med 2011; 37:895.</a></li><li><a class="nounderline abstract_t">Qin L, Ren L, Wan S, et al. Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General Anesthetics. J Med Chem 2017; 60:3606.</a></li><li><a class="nounderline abstract_t">Liao J, Li M, Huang C, et al. Pharmacodynamics and Pharmacokinetics of HSK3486, a Novel 2,6-Disubstituted Phenol Derivative as a General Anesthetic. Front Pharmacol 2022; 13:830791.</a></li><li><a class="nounderline abstract_t">Liu Y, Peng Z, Liu S, et al. Efficacy and Safety of Ciprofol Sedation in ICU Patients Undergoing Mechanical Ventilation: A Multicenter, Single-Blind, Randomized, Noninferiority Trial. Crit Care Med 2023; 51:1318.</a></li></ol></div><div id="topicVersionRevision">Topic 1616 Version 74.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30113379" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12195434" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1922897" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : [A case of superficial lymph node tuberculosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19228970" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The involvement of hypothalamic sleep pathways in general anesthesia: testing the hypothesis using the GABAA receptor beta3N265M knock-in mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12475885" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26675952" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut†.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27145556" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Is Propofol Safe For Food Allergy Patients? A Review of the Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8536552" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432154" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630539" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sedation of critically ill patients during mechanical ventilation. A comparison of propofol and midazolam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19923937" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Propofol infusion syndrome: difficult to recognize, difficult to study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33274340" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Incidence of Propofol-Induced Hypertriglyceridemia and Identification of Associated Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33985368" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Safety of Continuous Infusion Propofol in Mechanically Ventilated Adults With Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36053664" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Triglyceride Concentrations and Their Relationship to Sedation Choice and Outcomes in Mechanically Ventilated Patients Receiving Propofol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36053664" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Triglyceride Concentrations and Their Relationship to Sedation Choice and Outcomes in Mechanically Ventilated Patients Receiving Propofol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214693" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hemodynamic effects of propofol: data from over 25,000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791816" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Postoperative infections traced to contamination of an intravenous anesthetic, propofol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7600841" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prolonged propofol sedation in the critical care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10999506" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical significance of rare and benign side effects: propofol and green urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7598270" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Appearance of white urine during propofol anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18575838" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The use of propofol for medium and long-term sedation in critically ill adult patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30857601" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Propofol infusion syndrome: a structured literature review and analysis of published case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17144001" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The 'propofol infusion syndrome': myth or menace?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17567345" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Propofol infusion syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18664783" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Predictors of mortality in patients with suspected propofol infusion syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12665397" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Propofol: a review of its use in intensive care sedation of adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782764" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Propofol-related infusion syndrome: rare and fatal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844346" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Propofol infusion syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21464061" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Analytic reviews: propofol infusion syndrome in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15281533" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical management of cardiogenic shock associated with prolonged propofol infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19412155" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Propofol infusion syndrome: update of clinical manifestation and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558515" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Propofol infusion syndrome: an unusual cause of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874582" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661801" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1656882" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Uncoupling effect of the general anesthetic 2,6-diisopropylphenol in isolated rat liver mitochondria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8898917" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mechanisms of inhibition and uncoupling of respiration in isolated rat liver mitochondria by the general anesthetic 2,6-diisopropylphenol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8363078" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intravenous or epidural clonidine for intra- and postoperative analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1672579" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Interaction between opiate subtype and alpha-2 adrenergic agonists in suppression of noxiously evoked activity of WDR neurons in the spinal dorsal horn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31862730" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intranasal Dexmedetomidine for Procedural Distress in Children: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28105598" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10737913" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Influence of cardiac output on dexmedetomidine pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22030215" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173557" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24558330" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Interpatient variability in dexmedetomidine response: a survey of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22436955" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35648198" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910487" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effects of increasing plasma concentrations of dexmedetomidine in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19682844" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27722111" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Predictors of dexmedetomidine-associated hypotension in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20376429" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26889269" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of different doses of dexmedetomidine on heart rate and blood pressure in intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499610" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dexmedetomidine sedation leading to refractory cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499610" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Dexmedetomidine sedation leading to refractory cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33813941" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Incidence of Fever Associated With Dexmedetomidine in the Adult Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33554338" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fever Associated With Dexmedetomidine in Adult Acute Care Patients: A Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2842132" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The benzodiazepine receptor: a pharmacological control element of brain function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6137558" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6111408" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical pharmacokinetics of oxazepam and lorazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902253" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6138083" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9726743" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18073360" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394685" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17384929" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Precipitants of post-traumatic stress disorder following intensive care: a hypothesis generating study of diversity in care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082703" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050611" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26404392" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Benzodiazepine-associated delirium in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35505432" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sequential use of midazolam and dexmedetomidine for long-term sedation may reduce weaning time in selected critically ill, mechanically ventilated patients: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188334" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19598594" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Complications of Intravenous Diazepam - Adverse Psychological Reactions. (An assessment of 16,000 cases).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8659737" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Reversal of a paradoxical reaction to midazolam with flumazenil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710082" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Completion of upper endoscopic procedures despite paradoxical reaction to midazolam: a role for flumazenil?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710082" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Completion of upper endoscopic procedures despite paradoxical reaction to midazolam: a role for flumazenil?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961161" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560204" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162774" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10991709" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Propylene glycol toxicity in a patient receiving intravenous diazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286548" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657015" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16422667" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555487" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Recognition, treatment, and prevention of propylene glycol toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10628896" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pharmacokinetics of haloperidol: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16841959" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16841959" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33629327" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8124994" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Continuous infusion of haloperidol controls agitation in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3379030" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment of severe, refractory agitation with a haloperidol drip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8520081" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Use of haloperidol infusions to control delirium in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24461612" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30346242" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36286254" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Haloperidol for the Treatment of Delirium in ICU Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33426981" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A Retrospective Comparison of the Effectiveness and Safety of Intravenous Olanzapine Versus Intravenous Haloperidol for Agitation in Adult Intensive Care Unit Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21934036" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2867465" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The management of depression and anxiety following myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1676622" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Treatment of delirium in the critically ill patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8463445" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8338292" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Torsade de pointes associated with the use of intravenous haloperidol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887805" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Implications of atypical antipsychotic prescribing in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3597329" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Decreased extrapyramidal symptoms with intravenous haloperidol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234500" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548409" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Antipsychotic drug use and mortality in older adults with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325327" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28833346" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Repurposing Valproate, Enteral Clonidine, and Phenobarbital for Comfort in Adult ICU Patients: A Literature Review with Practical Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35187497" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Multicenter Retrospective Review of Ketamine Use in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36504505" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Ketamine Infusion for Sedation and Analgesia during Mechanical Ventilation in the ICU: A Multicenter Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35081769" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Impact of Ketamine on Analgosedative Consumption in Critically Ill Patients: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21773855" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : A systematic review of intravenous ketamine for postoperative analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444449" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Very-low-dose ketamine for the management of pain and sedation in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412369" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A comprehensive review of opioid-induced hyperalgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28067704" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Intravenous Ketamine Infusions for Neuropathic Pain Management: A Promising Therapy in Need of Optimization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24945127" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Topical and peripheral ketamine as an analgesic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35606831" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36750971" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Profile of liver cholestatic biomarkers following prolonged ketamine administration in patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618805" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Ketamine for perioperative pain management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804361" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain[ISRCTN83088383].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317593" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The Reemergence of Ketamine for Treatment in Critically Ill Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9989340" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Clinical pharmacokinetics of sevoflurane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21445640" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Volatile agents for ICU sedation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28430430" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General Anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35185584" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Pharmacodynamics and Pharmacokinetics of HSK3486, a Novel 2,6-Disubstituted Phenol Derivative as a General Anesthetic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37272947" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Efficacy and Safety of Ciprofol Sedation in ICU Patients Undergoing Mechanical Ventilation: A Multicenter, Single-Blind, Randomized, Noninferiority Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
